Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Bristol-Myers Squibb CompanyNYSE: BMY
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $2.63B (cash outflow) rose 43.2% year over year, ahead of the +40.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 68.6% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Financing cash flow amounted to 21.5% of revenue in FY2025, up 10.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +43.2% holds above the trailing-twelve-month pace of +40.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (10.35B) USD
- Year-over-year change
- -301.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.35B) | -301.8% |
| FY2024 | 2024-12-31 | 5.13B | +154.4% |
| FY2023 | 2023-12-31 | (9.42B) | +44.5% |
| FY2022 | 2022-12-31 | (16.96B) | -4.5% |
| FY2021 | 2021-12-31 | (16.22B) | — |
Financing Cash Flow vs competitors
How BMY compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +40.7% is the 5th highest of 11, against a peer median of +11.1%.
- Financing cash flow amounts to 23.8% of revenue for BMY, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $18.15B USD | +229.4% | -14.5% | 18.3% | |
| LTM Jun 2026 | $12.89B USD | -7.3% | -19.9% | 20.0% | |
| LTM Jun 2026 | $11.71B USD | +40.7% | -15.2% | 23.8% | |
| LTM Jun 2026 | $8.4B USD | -53.8% | -11.4% | 13.2% | |
| LTM Jun 2026 | $6.17B USD | +141.8% | -40.5% | 9.3% | |
| LTM Sep 2026 | $5.39B USD | +9.1% | +3.4% | 8.7% | |
| LTM Jun 2026 | $4.65B USD | +13.0% | +6.2% | 15.3% | |
| LTM Jun 2026 | $4.13B USD | -65.2% | +39.1% | 10.8% | |
| LTM Jun 2026 | $2.61B USD | +2060.9% | -25.8% | 3.3% | |
| LTM Jun 2026 | £2.53B GBP | -29.6% | — | 7.6% | |
| LTM Jun 2026 | $472.2M USD | +102.8% | -10.1% | 0.8% | |
| Peer median (excluding BMY) | — | +11.1% | -11.4% | 10.1% | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.01B | 6.35B | 8.04B | (8.93B) | 7.06B |
| Depreciation & Amortization | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B |
| Deferred Income Tax | (1.39B) | (2.74B) | (3.29B) | (2.09B) | (965M) |
| Stock-Based Compensation | 583M | 457M | 518M | 507M | 553M |
| Change in Working Capital | (1.26B) | (2.23B) | (1.91B) | 810M | (455M) |
| Accounts Receivables | (1.05B) | (663M) | (995M) | 264M | (295M) |
| Inventory | 13M | (69M) | (751M) | (486M) | (184M) |
| Accounts Payables | 245M | 109M | 198M | 184M | (2M) |
| Other Working Capital | (465M) | (1.61B) | (366M) | 848M | 26M |
| Other Non-Cash Items | 578M | 955M | 744M | 15.3B | 3.96B |
| Operating Cash Flow | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B |
| Capital Expenditures | (973M) | (1.12B) | (1.21B) | (1.25B) | (1.31B) |
| Acquisitions (Net) | (862M) | (2.98B) | (260M) | (20.72B) | (2.87B) |
| Purchases of Investments | (5.48B) | (3.59B) | (1.77B) | (769M) | (2B) |
| Sales of Investments | 6.78B | 6.63B | 948M | 1.39B | 2.05B |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (538M) | (1.06B) | (2.3B) | (21.35B) | (4.13B) |
| Debt Repayment | (6.18B) | (5.31B) | 456M | 10.1B | (5.18B) |
| Common Stock Issued | 0 | 0 | 0 | (106M) | (128M) |
| Common Stock Repurchased | (6.29B) | (8B) | (5.16B) | 0 | 0 |
| Dividends Paid | (4.4B) | (4.63B) | (4.74B) | (4.86B) | (5.05B) |
| Other Financing Activities | 641M | 984M | 27M | 0 | 0 |
| Financing Cash Flow | (16.22B) | (16.96B) | (9.42B) | 5.13B | (10.35B) |
| Effect of Forex Changes | (102M) | (33M) | 45M | (137M) | 187M |
| Net Change in Cash | (657M) | (4.99B) | 2.19B | (1.17B) | (137M) |
| Free Cash Flow | 15.23B | 11.95B | 12.65B | 13.94B | 12.85B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.